OncoCyte Corp (NYSE:OCX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday.

According to Zacks, “OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. “

OCX has been the subject of a number of other research reports. Benchmark Co. increased their price target on shares of OncoCyte Corp from $7.50 to $8.00 and gave the company a “speculative buy” rating in a report on Tuesday, June 7th. Canaccord Genuity reaffirmed a “buy” rating on shares of OncoCyte Corp in a report on Wednesday, June 15th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/oncocyte-corp-ocx-downgraded-by-zacks-investment-research.html

Shares of OncoCyte Corp (NYSE:OCX) opened at 4.5701 on Thursday. The company’s market capitalization is $116.22 million. The stock has a 50 day moving average price of $4.02 and a 200-day moving average price of $4.44. OncoCyte Corp has a 12 month low of $2.45 and a 12 month high of $10.24.

OncoCyte Corp (NYSE:OCX) last announced its quarterly earnings results on Thursday, August 11th. The company reported ($0.10) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.01. Analysts forecast that OncoCyte Corp will post $0.04 EPS for the current year.

OncoCyte Corp Company Profile

OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.

5 Day Chart for NYSE:OCX

Receive News & Ratings for OncoCyte Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Corp and related companies with MarketBeat.com's FREE daily email newsletter.